TFR

Trading

Floor Research

Welcome to the

Trading Floor

8/04/26

This Trading Floor Research report contains:

Sector Update

A Weekly Follow-up of Current Stock Positions

Sector Update

Of the seven sectors that closed higher today, only **healthcare** and **basic materials** saw above-average volume, confirming their moves. Basic materials volume was just fractionally higher. While this was enough to confirm a new buy signal, it did not significantly lift overall accumulation off year-to-date lows. As a result, I consider new purchases in the sector to carry more risk than I'm willing to accept.

Healthcare entered the session with the strongest accumulation in the market. Today's 0.41% advance on a 36.2% increase in volume reinforces its leadership. That's why my focus remains on **healthcare** and **biotech's**, the strongest group within the sector.

This strength was evident in my position in **MBX Therapeutics (MBX),** which hit its first Fibonacci target, prompting me to sell a third of my position for an 8.7% gain. With healthcare currently the only sector showing reliable price strength, my only purchase today was **Inhibikase Therapeutics (IKT),** an emerging biotech leader that confirmed today's buy on volume 47.6% above average. Overall accumulation is soaring as IKT breaks out of its eight-month base.

The lack of volume made it impossible for any other sector with a price advance to confirm a new buy signal, and until volume appears, sectors like **technology** continue to carry tremendous risk.

Healthcare Sector

MBX Therapeutics (MBX)



8/04/26

TFR

Trading

Floor Research

Welcome to the Trading Floor

This Trading Floor Research report is the weekly follow-up:

(Please, watch this list closely. If a stock does not appear in this list, it has been sold or was never purchased)

- **Trivago (TRVG) was purchased on June 16 at 4.31.** On June 23, I sold a third of the position at 5.02, locking in a 16.5% gain. On July 1, I sold another third of the position at the second Fibonacci target with a 35.3% gain. TRVG closed at 5.48.

- **MBX Therapeutics (MBX) was purchased on July 30 at 64.46**. On August 4, I sold a third of the position at 70.06, locking in an 8.7% gain. MBX closed at 70.70.

- **Inhibikase Therapeutics (IKT) was purchased on August 4 at 2.37**. IKT closed at 2.44.

Disclaimer

Before using this site, please make sure that you note the following important information:

Do your Own Research

Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on our Website and wish to rely upon, whether for the purpose of making an investment decision or otherwise.

The content of this email is confidential and intended only for the recipient specified in the message. It is strictly forbidden to share any part of this message with any third party without the written consent of the sender. If you received this message by mistake, please reply to this message and follow with its deletion so that we can ensure such a mistake does not occur in the future.

TFR

Trading Floor Research

Welcome to the Trading Floor

The results are not (or may not be) representative of the performance of all selections made by the Trading Floor Research (TFR) newsletter.

We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. **Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.** This material is being provided for informational purposes only, and nothing herein constitutes investment, legal, accounting, or tax advice or a recommendation to buy, sell, or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors, or markets identified and described were or will be profitable. All information is current as of the date herein and is subject to change without notice.